For Australians with rare cancers the costs of treatment are "absolutely unsustainable," patient advocates say.
Noel Carmona was diagnosed with stage four thymic carcinoma in early 2023 and paid almost $20,000 for immunotherapy that ultimately failed.
"Can you imagine being told that you've got stage four cancer, and then on top of that you were told that you had to pay three rounds every three weeks just to live?" Mr Carmona said.
